1	Fanconi anemia proteins counteract the implementation of the
2	oncogene-induced senescence program
3	
4	Anne HELBLING-LECLERC ^{1,2,3} , Françoise DESSARPS-FREICHEY ^{1,2,3} , Caroline
5	EVRARD ^{1,2,3} and Filippo ROSSELLI ^{1,2,3}
6	
7	¹ UMR8200-CNRS, Gustave Roussy, Villejuif Cedex, France
8	² Université Paris-Sud, Université Paris-Saclay, Orsay, France
9	³ Equipe labellisée "La Ligue Contre le Cancer".
10	
11	
12	
13	
14	Correspondence:
15	Anne Helbling-Leclerc and Filippo Rosselli, UMR 8200 - CNRS - Gustave Roussy,
16	PR2, 114 rue Edouard VAILLANT, 94805 VILLEJUIF Cedex;
17	phone: +33(0)41.11.51.16; fax:+33 (0)1.42.11.52.44
18	Email: anne.helbling-leclerc@gustaveroussy.fr & filippo.rosselli@gustaveroussy.fr
19	
20	

21

SUPPLEMENTAL DATA LEGENDS

- 22
- S1A and S1B. Example of cell cycle profiles obtained by FACS analysis of BrdU
 and PI stained IMR90* and WI38* cells.
- 25

S2A. Representative Western blots showing the time course expression of
 indicated protein in WI38*-oncogene activated cells proficient or deficient in
 FANCD2.

29

S2B. Quantitative analysis of the expression of the proteins analyzed as in S2A.

Bar represent the mean +/_ SEM of at least 3 independent experiments. *p<0.05.

32

S2C. Quantitative analysis of FANCD2 expression at the indicated time point in
 oncogene-activated WI38* cells. Bars represent the mean +/- SEM of at least 3
 independent experiments. *p< 0.05; **p<0.01.

36

S2D. Graphics present the time course expression of each indicated proteins
 relative in presence or absence of FANCD2 in IMR90* or WI38*-oncogne
 activated cells. Each point is mean +/- SEM of at least 3 independent
 experiments.

- 41
- 42





Supplemental Figure 1. Helbling-Leclerc et al.

S1A



siLacZ

siFANCD2











WI38*



